" class="no-js "lang="en-US"> Alexander Schuth - Medtech Alert
Wednesday, September 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Alexander Schuth

Alexander Schuth

About Alexander Schuth

Alexander Schuth is a co-founder of Denali Therapeutics and has served as the Chief Operating Officer and Secretary since 2015. He led the establishment of several strategic partnerships at Denali, including with Biogen, Sanofi and Takeda, and oversaw the growth and management of Denali’s broad therapeutic portfolio.

Related Story

Artificial Intelligence

 PharmEnable Announces Multi-target Collaboration With Denali Therapeutics in Neurodegenerative Disease | Pharmtech Focus

PharmEnable Announces Multi-target Collaboration With Denali Therapeutics in Neurodegenerative Disease

May 30 2022

PharmEnable, an AI drug-discovery company mapping unexplored chemical space to deliver innovative medicines, has announced […]